The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jeong, Sun Young | - |
dc.contributor.author | Hong, Jung Yong | - |
dc.contributor.author | Park, Joon Oh | - |
dc.contributor.author | Park, Young Suk | - |
dc.contributor.author | Lim, Ho Yeong | - |
dc.contributor.author | Jang, Jae Yeon | - |
dc.contributor.author | Jeon, Youngkyung | - |
dc.contributor.author | Kim, Seung Tae | - |
dc.date.accessioned | 2023-12-13T20:31:49Z | - |
dc.date.available | 2023-12-13T20:31:49Z | - |
dc.date.issued | 2023-06 | - |
dc.identifier.issn | 1756-283X | - |
dc.identifier.issn | 1756-2848 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/25096 | - |
dc.description.abstract | Background: With a 15% incidence, KRAS is one of the most common mutations in biliary tract cancer (BTC) and is a poor prognostic factor. Immune checkpoint inhibitors (ICIs) as salvage therapy have modest activity in BTC. Objectives: There are limited data on the efficacy of ICIs according to KRAS mutation in BTC. We evaluated the efficacy of ICIs in BTC patients with or without KRAS mutations. Design: Retrospective observational study. Methods: We conducted molecular profiling in BTC patients who received ICIs as salvage therapy. The expression of programmed death ligand 1 (PD-L1) on tumor cells was assessed using immunohistochemistry. The TruSight (TM) Oncology 500 assay from Illumina was used as a cancer panel. We analyzed overall survival (OS) and progression-free survival (PFS) of ICI in BTC patients according to KRAS mutation and PD-L1 expression. Results: A total of 62 patients were included in this analysis. The median age was 68.0 years; 47 patients (75.8%) received pembrolizumab and 15 (24.2%) received nivolumab as salvage therapy. All patients received gemcitabine plus cisplatin as the frontline therapy, and 53.2% received fluoropyrimidine plus oxaliplatin (FOLFOX) before ICI. The median number of lines of prior chemotherapy was 2.5. The KRAS mutation was found in 13 patients (19.1%), and 28 patients (45.2%) showed 1% or more of tumor cells out of visible tumor cells positive for PD-L1. There was no statistical correlation between KRAS mutation and PD-L1 expression. The median OS and PFS with ICI were 5.6 [interquartile range (IQR): 3.3-8.0] and 3.8 (IQR: 3.0-4.5) months, respectively. There were no statistically significant differences in PFS with ICIs according to KRAS mutation (mutant type versus wild type) and PD-L1 expression (positive versus negative). In subgroup analysis, patients with both KRAS mutation and PD-L1 positivity had longer PFS compared with patients with KRAS mutation and PD-L1 negativity (10.1 versus 2.6 months, p = 0.047). This finding was not shown in patients with wild-type KRAS. Conclusion: Our analysis suggested that PD-L1 expression might be a useful biomarker for ICIs in BTC patients with KRAS mutation but not in those with wild-type KRAS. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | SAGE Publications | - |
dc.title | The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1177/17562848231170484 | - |
dc.identifier.scopusid | 2-s2.0-85158088822 | - |
dc.identifier.wosid | 000981346700001 | - |
dc.identifier.bibliographicCitation | Therapeutic Advances in Gastroenterology, v.16 | - |
dc.citation.title | Therapeutic Advances in Gastroenterology | - |
dc.citation.volume | 16 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | PD-L1 EXPRESSION | - |
dc.subject.keywordAuthor | biliary tract cancer | - |
dc.subject.keywordAuthor | immune checkpoint inhibitor | - |
dc.subject.keywordAuthor | KRAS mutation | - |
dc.subject.keywordAuthor | PD-L1 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.